[go: up one dir, main page]

Steinbrecher et al., 1984 - Google Patents

Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism

Steinbrecher et al., 1984

Document ID
9116682339371279777
Author
Steinbrecher U
Witztum J
Publication year
Publication venue
Diabetes

External Links

Snippet

In previous studies we have shown that extensive glucosylation of low-density lipoproteins (LDL)(40% of lysines modified) completely blocks receptor-mediated degradation in animals and in man. Other studies indicated that in some diabetics up to 5% of lysine residues of …
Continue reading at diabetesjournals.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons

Similar Documents

Publication Publication Date Title
Steinbrecher et al. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism
Brownlee et al. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein
Samols et al. Studies on tissue uptake of insulin in man using a differential immunoassay for endogenous and exogenous insulin
Hirschberg et al. Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat.
LeRoy Increased collagen synthesis by scleroderma skin fibroblasts in vitro a possible defect in the regulation or activation of the scleroderma fibroblast
Guma et al. Insulin induces translocation of GLUT-4 glucose transporters in human skeletal muscle
Witztum et al. Nonenzymatic glucosylation of high-density lipoprotein accelerates its catabolism in guinea pigs
Durrington et al. Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes
Tape et al. Apolipoprotein AI and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis
Stone et al. Radioimmunoassay of myoglobin in human serum. Results in patients with acute myocardial infarction.
Kesäniemi et al. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.
Fielding et al. Human noninsulin-dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by selective immunoadsorption of apolipoprotein E.
Rasio et al. Diffusion of glucose, insulin, inulin, and Evans blue protein into thoracic duct lymph of man
Pickup et al. Serum sialic acid concentration and coronary heart disease in NIDDM
Goldwasser et al. [7] Erythropoietin: Assay and study of its mode of action
EP0259893B1 (en) Agents for removing advanced glycosylation endproducts
Van Tol et al. High density lipoprotein catabolism before and after partial hepatectomy
Lundholm et al. Transport kinetics of amino acids across the resting human leg.
Storstein et al. Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin
Boberg Heparin‐released blood plasma lipoprotein lipase activity in patients with hyperlipoproteinemia
Zhang et al. Glycation amplifies lipoprotein (a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells
Stein et al. Use of 3H-cholesteryl linoleyl ether for the quantitation of plasma cholesteryl ester influx into the aortic wall in hypercholesterolemic rabbits.
Yue et al. Non-enzymatic glycosylation of tissue protein in diabetes in the rat
Kazal et al. The measurement of erythropoietin
Gulan et al. Biosynthetic human insulin improves postprandial glucose excursions in type I diabetes